07.18.22
Pharmactive Biotech Products, is making strides into the sports nutrition market with results from recent research on its affron natural saffron ingredient published in JISSN.
The clinical study demonstrated that affron improved enjoyment of sports in active adults, and, in males, it can help increase the resilience to stress and anxiety by increasing the cardiac parasympathetic response that regulates post-exercise heart rate.
“While most consumers agree exercise and physical activity are vital, especially after so many have spent too much of the past three years in lockdown, for most people routine exercise three times a week is hard, and often is boring,” said Jean-Marie Raymond, CEO for Pharmactive. “But if it’s possible to better enjoy the activity, it can create positive feedback that encourages doing more and maintaining a routine much longer.”
The six-week, randomized, double-blind, placebo-controlled trial included healthy, nonprofessional participants, aged 18 to 65 years, who performed moderate-to-intense aerobic exercise more than three times per week. Activities included such exercises as cycling, running, swimming, tennis, aerobics, and/or boxing. Study subjects were chosen using strict exclusion criteria; 62 volunteers participated in the study, and 59 completed it; each subject took 14 mg of affron, two times per day.
The clinical study demonstrated that affron improved enjoyment of sports in active adults, and, in males, it can help increase the resilience to stress and anxiety by increasing the cardiac parasympathetic response that regulates post-exercise heart rate.
“While most consumers agree exercise and physical activity are vital, especially after so many have spent too much of the past three years in lockdown, for most people routine exercise three times a week is hard, and often is boring,” said Jean-Marie Raymond, CEO for Pharmactive. “But if it’s possible to better enjoy the activity, it can create positive feedback that encourages doing more and maintaining a routine much longer.”
The six-week, randomized, double-blind, placebo-controlled trial included healthy, nonprofessional participants, aged 18 to 65 years, who performed moderate-to-intense aerobic exercise more than three times per week. Activities included such exercises as cycling, running, swimming, tennis, aerobics, and/or boxing. Study subjects were chosen using strict exclusion criteria; 62 volunteers participated in the study, and 59 completed it; each subject took 14 mg of affron, two times per day.
